Trials / Terminated
TerminatedNCT01264159
Preemptive Lung Impedance-guided Therapy of Evolving Acute Heart Failure in Acute Myocardial Infarction Patients
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 70 (actual)
- Sponsor
- Hillel Yaffe Medical Center · Other Government
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
It is well known that 20-25% of patients hospitalized for acute myocardial infarction will develop acute heart failure during their hospitalization. Currently, the investigators have no reliable parameter for prediction of evolving acute heart failure in such a group of patients. As a result, the investigators have no way of preventing acute heart failure. Treatment of these patients only begins after appearance of clinical signs of acute heart failure. Lung impedance monitoring may be a good non-invasive parameter for prediction of evolving acute heart failure. This study will attempt to address whether preemptive lung impedence-guided therapy may prevent the development of overt acute heart failure and improve their clinical outcome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Lung impedence-guided therapy | |
| OTHER | Usual treatment of patients with developing acute heart failure |
Timeline
- Start date
- 2011-01-01
- Primary completion
- 2015-01-01
- Completion
- 2015-07-01
- First posted
- 2010-12-21
- Last updated
- 2020-06-11
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT01264159. Inclusion in this directory is not an endorsement.